Am J Blood Res 2011;1(1):57-64
Review Article
The evolving role of statins in hematopoietic stem and progenitor cell
transplantation
Mehdi Hamadani, Michael D. Craig, Laura F. Gibson, Scot C. Remick
Osborn Hematopoietic Malignancy and Transplantation Program, MBRCC, West Virginia University, Morgantown, WV, USA.
Received May 11, 2011; accepted May 27, 2011; Epub June 1, 2011; published June 15, 2011
Abstract: Allogeneic hematopoietic stem cell transplantation is the sole curative modality for a variety of malignant and benign
hematological disorders. Despite advances in supportive care and transplant conditioning regimens graft-versus-host
disease (GVHD), infectious complications and end organ toxicity remain the leading causes of transplant related mortality
(TRM). Development of safe and effective strategies to mitigate these significant complications associated with HSCT, are
urgently needed. Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, with
a well defined toxicity profile. Statins have pleiotropic immunomodulatory effects which are relevant in the context of treating
and preventing GVHD. In addition to GVHD statins may possess several other effects that might have clinical benefit in the
setting of hematopoietic cell transplantation, such as treatment of bronchiolitis obliterans and antineoplastic activity. Herein
we review the emerging role of statins in improving the outcomes of patients undergoing HSCT. (AJBR1105003).
Keywords: Statin, atorvastatin, GVHD, HMG-CoA reductase inhibitors, allogeneic stem cell transplantation, multiple myeloma,
idiopathic pulmonary fibrosis, graft-versus-host disease
Full Text PDF
Address all correspondence to:
Mehdi Hamadani, M.D.
Assistant Professor of Medicine
Osborn Hematopoietic Malignancy and Transplantation Program
West Virginia University
Morgantown, WV 26506
Tel: (304) 293-3709
Fax: (304) 598-4522
E-mail: shamadani@hsc.wvu.edu
Review Article
The evolving role of statins in hematopoietic stem and progenitor cell
transplantation
Mehdi Hamadani, Michael D. Craig, Laura F. Gibson, Scot C. Remick
Osborn Hematopoietic Malignancy and Transplantation Program, MBRCC, West Virginia University, Morgantown, WV, USA.
Received May 11, 2011; accepted May 27, 2011; Epub June 1, 2011; published June 15, 2011
Abstract: Allogeneic hematopoietic stem cell transplantation is the sole curative modality for a variety of malignant and benign
hematological disorders. Despite advances in supportive care and transplant conditioning regimens graft-versus-host
disease (GVHD), infectious complications and end organ toxicity remain the leading causes of transplant related mortality
(TRM). Development of safe and effective strategies to mitigate these significant complications associated with HSCT, are
urgently needed. Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, with
a well defined toxicity profile. Statins have pleiotropic immunomodulatory effects which are relevant in the context of treating
and preventing GVHD. In addition to GVHD statins may possess several other effects that might have clinical benefit in the
setting of hematopoietic cell transplantation, such as treatment of bronchiolitis obliterans and antineoplastic activity. Herein
we review the emerging role of statins in improving the outcomes of patients undergoing HSCT. (AJBR1105003).
Keywords: Statin, atorvastatin, GVHD, HMG-CoA reductase inhibitors, allogeneic stem cell transplantation, multiple myeloma,
idiopathic pulmonary fibrosis, graft-versus-host disease
Full Text PDF
Address all correspondence to:
Mehdi Hamadani, M.D.
Assistant Professor of Medicine
Osborn Hematopoietic Malignancy and Transplantation Program
West Virginia University
Morgantown, WV 26506
Tel: (304) 293-3709
Fax: (304) 598-4522
E-mail: shamadani@hsc.wvu.edu
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |